kl03042.htm  


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
                                                        
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  March 12, 2013
               

SIGA TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

Delaware
0-23047
13-3864870
(State or other jurisdiction of
incorporation or organization)
(Commission file number)
(I.R.S. employer
identification no.)

35 East 62nd Street
New York, New York
(Address of principal executive offices)
 
 
10065
(Zip code)

Registrant’s telephone number, including area code:  (212) 672-9100
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 

 
 

 

Item 8.01.    Other Events.

On March 12, 2013, SIGA Technologies, Inc., a Delaware corporation (“SIGA”), issued a press release announcing the delivery of approximately 190,000 courses of its proprietary smallpox antiviral drug, Arestvyr™, to the United States Government’s Strategic National Stockpile.  This delivery is the first of a series of deliveries of Arestvyr™ pursuant to SIGA’s contract with the Biomedical Advanced Research and Development Authority.

Item 9.01.    Financial Statements and Exhibits.
 
(c) Exhibits
 
Exhibit No.
Description
 
99.1
 
Press Release, dated March 12, 2013
 


 
 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
SIGA TECHNOLOGIES, INC.
 
By: /s/ Daniel J. Luckshire              
   Name: Daniel J. Luckshire
   Title:   Chief Financial Officer
 
 
Date:  March 13, 2013